SCHEMBL10284080

SCHEMBL10284080

COc1cc(CNc2ccc(CC3CNc4ncncc43)c(F)n2)ccn1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 17/20 0.42
▸ CYP2C9 P11712 7/20 0.42
▸ CYP1A2 P05177 4/20 0.39
▸ KIT P10721 2/20 0.36
▸ KDR P35968 2/20 0.36
▸ FLT3 P36888 2/20 0.36
▸ AURKC Q9UQB9 2/20 0.36
▸ PDE5A O76074 1/20 0.36
▸ CYP2C19 P33261 4/20 0.35
▸ CSF1R P07333 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ ALOX15 P16050 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ CLK4 Q9HAZ1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2600096 0.89 CYP3A4 (0.51) CYP3A4CYP2C9CYP1A2PDE5ACYP2C19
SCHEMBL2600102 0.89 CYP3A4 (0.50) CYP3A4CYP2C9CYP1A2KITKDR
SCHEMBL2600093 0.89 CYP3A4 (0.52) CYP3A4CYP2C9CYP1A2KITKDR
SCHEMBL2600095 0.86 CYP3A4 (0.40) CYP3A4CYP2C9CYP1A2KITKDR
SCHEMBL10284257 0.83 CYP3A4 (0.51) CYP3A4CYP2C9CYP1A2KITKDR
SCHEMBL10284256 0.82 CYP3A4 (0.44) CYP3A4CYP2C9CYP1A2ALDH1A1CLK4
SCHEMBL2600075 0.82 CYP3A4 (0.54) CYP3A4CYP2C9CYP1A2KITKDR
SCHEMBL2600099 0.79 CYP3A4 (0.49) CYP3A4CYP2C9KITKDRFLT3
SCHEMBL2600097 0.78 MAP4K4 (0.40) CYP3A4CYP2C9CYP1A2FLT3CYP2C19
SCHEMBL2600066 0.77 CYP2C19 (0.38) CYP3A4CYP2C9CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158636-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2012-04-17 — — US disclosed
US-20090286782-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286782-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PRKDC, PRKACA, PRKACG CYP3A4 3734/4885CYP2C9 2880/4885CYP1A2 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback